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EGFR: exon 19 del 17 12 3 - 1 16.6 > 24
EGFR: L858R 8 3 5 - - 9.7 14.6
KRAS: codon 12 mutations 20 - 9 9 2 3.8 15.5
KRAS: other mutations 4 - 1 2 1 1.2 3.3
Conclusion: The role of speciﬁc EGFR and KRAS genotype merits 
further continued investigation. As several trials of ﬁrst-line geﬁtinib 
or erlotinib near completion, the ability to combine mutation data and 
clinical outcomes from increasing numbers of chemotherapy-naïve 
patients in a web-based database may yield more powerful insight into 
roles of speciﬁc mutations and help guide treatment decisions. We an-
ticipate the addition of a number of patients from Japan and from other 
trials in the coming months.
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Mechanisms of activating PI3K signaling in lung cancers that 
become resistant EGFR tyrosine kinase inhibitors
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Background: Cancers that are sensitive to EGFR inhibitors down-
regulate Phosphoinositide 3-Kinase (PI3K) signaling in response to 
these drugs. Inhibition of PI3K signaling appears to be critical for ErbB 
inhibitors to induce cell death. Although lung cancers with EGFR mu-
tation often have initial impressive responses to EGFR inhibitors, they 
invariably develop resistance. In 50% of such patients, a single second-
ary mutation, a substitution of methionine for threonine at position 
790 (T790M), has been identiﬁed. EGFR T790M is sufﬁcient to cause 
geﬁtinib resistance and leads to persistent ERBB3/PI3K/Akt signaling 
in the presence of geﬁtinib. However, the mechanisms by which the 
other half of cancers becomes resistant remain unidentiﬁed. 
Methods: To identify novel mechanisms of resistance, we cultured 
highly sensitive EGFR mutant and ampliﬁed cell lines in the presence 
of increasing concentrations of geﬁtinib until resistant cell lines were 
produced. 
Results: We found that, unlike the parental cells, all of the resistant cell 
lines maintain PI3K signaling in the presence of getitinib. Some cell 
lines use ErBB3 (i.e. no change from the parental cell line), whereas 
others utilize new adaptor proteins. Blocking the new mechanisms of 
activating PI3K leads to cellular death in the resistant cell lines.
Conclusions: Cancers that become resistant to EGFR inhibitors acquire 
novel mechanisms for activating PI3K. Inhibiting these pathways may 
be effective methods for treating cancers with acquired resistance to 
EGFR inhibitors.
Session D3: Pharmacogenomics &  
Biomarker in Cytotocix Chemotherapy 
Thursday, September 6
D3-01 Pharmacogenomics & Biomarker in Cytotocix Chemotherapy, Thu, 12:30 - 14:15
Genotyping single-nucleotide polymorphisms(SNP) in ERCC1, 
XPD, XRCC1, XRCC3 and MDR1 and CCND1 genes for response 
and toxicity prediction in chemotherapy of non small cell lung 
cancer (NSCLC)
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Background and Aim: SNP´s of DNA repair genes as well as SNP´s 
in MDR1 a CCND1 genes should serve as predictors of response to 
chemotherapy in NSCLC. The aim of this study was to ﬁnd SNP´s, 
their variants and combinations and their correlations to the response 
and toxicity for various cytostatic schedules. 
Material and Methods: Patients were divided according to prescribed 
cytostatics.There were several segregations,one using groups of 
patients treated by cisplatin or carboplatin, and another one separating 
patients treated by taxanes or vinorelbine vs.treated by gemcitabine. 
SNP´s were screened in DNA isolated from peripheral blood with the 
help of cycling-gradient capillary electrophoresis technique (CGCE) 
and standard DNA sequencing of PCR products. The following set of 
SNP markers was screened in all patients: ERCC1 Asn118Asn (C/T), 
ERCC2/XPD Lys751Gln (A/C), ERCC2/XPD Asp312Asn (G/A), 
XRCC1 Arg399Gln (G/A), XRCC3 Thr241Met (C/T), CCND1 A870G 
and MDR1 C3435T.
Results: The SNP set was screened in a total of 80 NSCLC patients. 
The group consisted of 57 males and 23 females, aged from 27 - 78 
with median 59.9 years. Overall response rates of chemotherapy 
induced leucotoxicity suffering patients were higher than thosesuffering 
from chemotherapy induced anaemias and/or thrombocytopenias. For 
ERCC1 (Asn118Asn), homozygous genotype T/T is associated with 
higher response rate followed by genotype C/T. The T/T patients also 
responded better to regimens including carboplatin than cisplatin. For 
XRCC1 (Arg399 Gln), genotype G/A exhibited more frequent response 
to chemotherapy than homozygous G/G. For XRCC3 (Thr241Met), 
homozygous genotype C/C is associated with higher response rate 
compared to homozygous T/T genotype. The C/C patients responded 
better to regimens including cisplatin than carboplatin. For MDR1 
(Ile1145Ile/C3435T), homozygous genotype C/C is associated with 
higher response rate compared to homozygous T/T. For CCND1 
(Pro241Pro), homozygous genotype A/A is associated with higher 
response rate compared to homozygous G/G. CCND1 genotype is as-
sociated with higher tumour response rate to taxanes/vinorelbine-plati-
num regimens, while genotype G/A is more sensitive to gemcitabine-
platinum derivatives.
Combination of several polymorphic markers seems to deliver promis-
ing results in prediction of response as well as toxicity. It enables 
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targeted prescription of chemotherapy with appropriate platinum com-
bination.
Authors would like to thank Barbora Belsanova for help with geno-
typing experiments. This work was supported by the Internal Grant 
Agency of the Czech Ministry of Health project number NR/9087-3.
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Background: Ethnic or racial differences in drug disposition (popula-
tion-related pharmacogenomics) may explain conﬂicting results of clin-
ical trials using similar treatment. We prospectively designed 3 separate 
phase III trials in advanced NSCLC (FACS & LC03 in Japan, S0003 in 
USA) with a paclitaxel-carboplatin “common arm” in order to compare 
outcomes. Differences in toxicity and efﬁcacy were noted between the 
2 Japanese studies and S0003 (Gandara, ASCO 05 & Crowley, ASCO 
06). We sought to determine whether these ﬁndings were due in part to 
PG alterations. 
Methods: Genomic DNA was prospectively collected from patients 
(pts) in 2 of these Phase III trials (LC03 [N=78, 37 on common arm] & 
S0003 [N=78]) with identical eligibility, staging, treatment paclitaxel 
(225mg/m2) & carboplatin (AUC 6), response & toxicity criteria. We 
analyzed for genotypic variants related to paclitaxel or platinum by 
pyrosequencing, & assessed results by Cox model for survival/PFS & 
logistics regression for response/toxicity.
Results: We will present an updated PG analysis for additional geno-
typic variants. There was a signiﬁcant difference between Japan & US 
pts in genotypes: CYP3A4*1b (p=.01), CYP3A5*3c (p=.03), ERCC2 
k751q (p < .001), and CYP2C8 r139k (p=.01). Genotypic correlations 
were observed between CYP3A4*1b for PFS (HR 2.75, 1.06-7.08, 
p=.04) & ERCC2 k751q for response (HR 0.33, 0.13-0.84, p=.02. For 
grade 4 neutropenia, the HR for ABCB1 3425c->T was 1.84 (0.77-
4.48), p=.19. 
Conclusions: 1) Japanese and US pts in these studies differed in al-
lelic distribution for genes involved in paclitaxel disposition or DNA 
repair. 2) Genotype-associated correlations were present for PFS 
(CYP3A4*1b) and response (ERCC2 k751q). 3) The small sample 
size limits interpretation of these data. 4) We will present plans for ad-
ditional prospectively designed trials exploring population-related PGs 
based on this common arm model. 
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Background: The International Adjuvant Lung Cancer Trial (IALT) 
demonstrated that adjuvant cisplatin-based chemotherapy increases 
the 5-survival rate by absolute 4% in patients with completely resected 
NSCLC. Selection of those patients who beneﬁt from chemotherapy 
would be of major clinical relevance. Clinical parameters such as age, 
gender or histology did not predict the beneﬁt of chemotherapy. Thus 
we initiated a translational research project termed IALT-Bio. The aim 
of this project is to study molecular biomarkers of tumors for their 
potential predictive values with regard to the effect of adjuvant chemo-
therapy on survival in IALT patients. 
Methods: Five groups of molecular biomarkers (19 markers in total) 
were studied: drug transporters, DNA repair, cell cycle regulators, sig-
nal transduction, apoptosis. Expression of biomarkers was determined 
by immunohistochemistry. Overall survival was analyzed with Cox 
models adjusted for clinical and pathological factors.
Results: Tumor specimens were collected from 867 patients from 28 
IALT centers. These patients represented 46% of all IALT patients and 
83% of the patients enrolled by the 28 centers. Collection of the tumor 
specimens of a world-wide clinical trial posed several problems includ-
ing ethical and logistic problems. All tumor specimens were pathologi-
cally examined and 783 samples were considered to be of sufﬁcient 
quality for further analyses. The laboratory analyses of the various bio-
markers were performed by several research groups. ERCC1 expres-
sion was shown to be of prognostic and predictive value. Patients with 
ERCC1-negative tumors beneﬁted (hazard ratio of death 0.65, 95% 
CI 0.5-0.86) from adjuvant chemotherapy, whereas no beneﬁt (hazard 
ratio 1.14, 95% CI 0.84-1.55) was seen in patients with ERCC1-posi-
tive tumors (p value for the comparison of the two hazard ratios: 0.009) 
(Olaussen KA et al., NEJM 2006, 355, 983). Similarly, absence of p27 
expression predicted beneﬁt of adjuvant chemotherapy (Filipits M et 
al., JCO 2007, in press). The corresponding hazard ratios were 0.66 
(95% CI 0.5-0.88) for patients with p27-negative tumors and 1.09 (95% 
CI 0.82-1.45) for those with p27-positive tumors, respectively (p value 
for the comparison of the two hazard ratios: 0.02). ERCC1 and p27 
were predictive independently of each other. When ERCC1 and p27 
were combined, the predictive values were further increased: the hazard 
ratios were 0.52 (95% CI 0.36-0.74) for patients with tumors nega-
tive for both biomarkers but 1.27 (95% CI 0.87-1.84) for those with 
tumors positive for both markers. These 2 groups comprised 58% of the 
patients. Multidrug resistance proteins (MRP1, MRP2) did not predict 
the outcome of adjuvant chemotherapy (Filipits M et al., manuscript 
submitted). Patients with FasL-negative tumors also beneﬁt from adju-
vant chemotherapy (Brambilla E et al., WCLC 2007). Analyses of other 
biomarkers including mutations of p53, k-ras and EGF receptor are still 
ongoing. Current research is attempting to validate these markers on 
patient populations from other adjuvant chemotherapy trials. 
Conclusions: Both ERCC1 and p27 are of predictive value in patients 
with completely resected NSCLC undergoing adjuvant cisplatin-based 
